Heart Failure | Norton Healthcare

Indication: Heart Failure

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to
Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Sub-indication: Heart Failure

Study Type: Drug Study

Principal Investigator: Kelly McCants, M.D.
Norton Heart & Vascular Institute

Sponsor: Sponsor: Merck & Co., Inc

Learn more at ClinicalTrials.gov

Email for more information: cvresearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.